Insider Transactions in Q2 2025 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 05
2025
|
Colleen F Reitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+35.04%
|
-
|
|
Jun 05
2025
|
Lee Nisley Newcomer Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+27.37%
|
-
|
|
Jun 05
2025
|
S. Louise Phanstiel Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+21.91%
|
-
|
|
Jun 05
2025
|
Mark Steven Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,148
+33.96%
|
-
|
|
Jun 05
2025
|
Paul Bisaro Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+35.64%
|
-
|
|
Jun 05
2025
|
Heinrich Dreismann Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+22.51%
|
-
|
|
Jun 05
2025
|
Daniel Skovronsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+26.83%
|
-
|
|
Jun 05
2025
|
Rashmi Kumar Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+28.14%
|
-
|
|
May 31
2025
|
Samraat S. Raha President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,498
+0.31%
|
$4,494
$3.56 P/Share
|
|
May 01
2025
|
Brian J Donnelly Chief Commerical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
397,534
+37.15%
|
-
|
|
Apr 14
2025
|
Mark Verratti Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,085
-0.28%
|
$8,680
$8.08 P/Share
|
|
Apr 14
2025
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
942
-0.55%
|
$7,536
$8.08 P/Share
|